相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET
Arnold Berkowitz et al.
NUCLEAR MEDICINE COMMUNICATIONS (2008)
Evaluation of a peptide ELISA for the detection of rituximab in serum
H. Blasco et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2007)
Pharmacokinetics of rituximab and its clinical use: Thought for the best use?
Guillaume Cartron et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity
Tom van Meerten et al.
CLINICAL CANCER RESEARCH (2006)
An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab
D Ternant et al.
THERAPEUTIC DRUG MONITORING (2006)
Pharmacokinetic behavior of rituximab - A study of different schedules of administration for heterogeneous clinical settings
MB Regazzi et al.
THERAPEUTIC DRUG MONITORING (2005)
Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders
LN Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the north central cancer treatment group
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as 'in vivo purge' and consolidative immunotherapy following autologous stem cell transplantation
J Mangel et al.
ANNALS OF ONCOLOGY (2003)
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance
T Manshouri et al.
BLOOD (2003)
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
O Manches et al.
BLOOD (2003)
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
T Igarashi et al.
ANNALS OF ONCOLOGY (2002)
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
P Colombat et al.
BLOOD (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
